Le Lézard
Classified in: Science and technology
Subject: Company Name Change

FLEETCOR Announces Rebranding to Corpay


FLEETCOR Technologies, Inc. (NYSE: FLT) ("the Company") a leading global payments Company, announced today it has rebranded the Company Corpay, Inc. The name change better reflects the Company's current portfolio of corporate payment solutions. The Company will begin trading today on the New York Stock Exchange under the new ticker symbol CPAY and the new CUSIP is 219948 106.

About Corpay

Corpay (NYSE: CPAY) is a global S&P500 corporate payments Company that helps businesses and consumers pay expenses in a simple, controlled manner. Corpay's suite of modern payment solutions help its customers better manage vehicle-related expenses (e.g. fueling and parking), travel expenses (e.g. hotel bookings) and payables (e.g. paying vendors). This results in our customers saving time and ultimately spending less. Corpay ? Payments made easy. To learn more visit www.corpay.com


These press releases may also interest you

at 14:28
ICEYE to deliver SAR satellites and data to Greece's National Satellite Space Project in collaboration with the European Space Agency
ICEYE, the global leader in synthetic aperture radar (SAR) satellite operations for Earth Observation, persistent monitoring, and natural catastrophe solutions, has today announced signing the contract for the Greek National Satellite Space Project...

at 13:01
AdvisorVault's 17a-4 Managed 365 Service: Finally, Guaranteed FINRA Compliance On The Microsoft Cloud
The AdvisorVault's 17a-4 Managed 365 Service includes full migration to Microsoft 365, a FINRA approved cybersecurity add on with a plug-in archiving data off the Microsoft cloud meeting the long-term electronic records retention & supervisory...

at 12:30
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca's proprietary computational pathology platform, quantitative continuous scoring (QCS), was predictive of clinical outcomes in patients...

at 12:30
Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Results from an exploratory analysis of the TROPION-Lung01 phase 3 trial showed TROP2 as measured by quantitative continuous scoring (QCS), AstraZeneca's proprietary computational pathology platform, was predictive of clinical outcomes in patients...

at 11:50
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was...

at 11:05
Coalition Announces Reinsurance Intermediary Coalition Re
Coalition, the world's first Active Insurance provider designed to prevent digital risk before it strikes, today announced the creation of its reinsurance intermediary, Coalition Re, to provide capacity for cyber reinsurance treaties and expand on...

More news about Science and technology...


News published on and distributed by: